SP-B Inhibitors
SP-B inhibitors, or surfactant protein B inhibitors, belong to a class of chemical compounds that have garnered significant interest in the field of pulmonary research and pharmacology. Surfactant protein B (SP-B) is a crucial component of the lung's surfactant system, a complex mixture of lipids and proteins that lines the alveoli and facilitates efficient gas exchange. SP-B, specifically, plays a vital role in reducing surface tension at the air-liquid interface within the lungs, preventing alveolar collapse during exhalation, and ensuring proper lung function. SP-B inhibitors are designed to modulate or inhibit the activity of this protein, thus affecting the surfactant system's function.
Chemically, SP-B inhibitors can take various forms, including small molecules or peptides, which are carefully designed to interfere with the functioning of SP-B. These inhibitors work by binding to SP-B or its associated molecules, disrupting the protein's ability to lower surface tension. By doing so, they can influence the stability of the lung's surfactant film, leading to alterations in the mechanics of breathing and gas exchange within the lungs. Research in this field has primarily focused on understanding the molecular interactions between SP-B and its inhibitors, as well as their effects on the surfactant system's physical properties. This knowledge could have implications for developing a deeper understanding of lung physiology and may have relevance in various respiratory conditions, although it is important to note that their practical applications and remain subjects of ongoing investigation and development.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone may downregulate SP-B expression by influencing glucocorticoid receptors and altering signaling pathways involved in lung development and surfactant production. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
Caffeine could potentially reduce SP-B expression by modulating cyclic AMP levels and affecting the signaling pathways that regulate surfactant protein synthesis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid, a derivative of vitamin A, may play a role in lung maturation and could influence SP-B expression by modulating signaling pathways and transcription factors involved in lung development. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide can affect various signaling pathways and transcription factors, potentially leading to a reduction in SP-B expression. Its teratogenic effects are well-known, and it may disrupt normal lung development. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic acid may inhibit histone deacetylase, influencing chromatin structure and potentially downregulating SP-B expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which could lead to changes in DNA methylation patterns and potentially result in reduced SP-B expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Like valproic acid, trichostatin A is a histone deacetylase inhibitor, and it may alter chromatin structure and decrease SP-B expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is involved in cell growth and protein synthesis. Inhibition of this pathway could lead to reduced SP-B expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin could potentially influence various cellular processes and reduce SP-B expression, though its effects on surfactant proteins are not well characterized. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin may cause cellular stress and damage, potentially leading to altered expression of genes, including those encoding surfactant proteins like SP-B. | ||||||